Fifty 410 vs LifeMD (2026): prices, structure, verdict

On tirzepatide, only LifeMD↗ has a rankable figure: $597 a month all-in; Fifty 410↗ publishes no maintenance-dose tirzepatide figure we could capture (advertised start: $133), so a like-for-like number does not exist.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only LifeMD has a rankable figure: $348 a month all-in; Fifty 410 does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fifty 410: the record, condensed

On tirzepatide, Fifty 410 advertises from $133 — and publishes no maintenance-dose figure we could capture. A starter-only price cannot be annualized, cannot be ranked, and should be treated as the bottom of an unstated range: before enrolling on its strength, get the 10 mg price in writing, and if the program will not state it, price the program at its ceiling rather than its floor.

Operationally at Fifty 410: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Fifty 410 page · visit Fifty 410 ↗

LifeMD: the record, condensed

LifeMD’s tirzepatide program bills $597 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at LifeMD is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Inside that $597 sits a mandatory $149-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $448, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #17 of 17 in the verified tirzepatide index — $382/month above the floor (NexLife↗, $215) — and sits $148 over the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $7,164.

LifeMD’s semaglutide program bills $348 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at LifeMD is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Inside that $348 sits a mandatory $149-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $199, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #20 of 20 verified programs, with the floor $215/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $1 a month. A year at this figure: $4,176 monthly-billed.

Operationally at LifeMD: shipping included; commitment program fee recurs monthly; cancellation program fee recurs until cancelled; pharmacy not publicly named — ask in writing before paying; states: 50 states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the LifeMD page · visit LifeMD ↗

§ Structure vs structure

Everything besides the price

Coverage: Fifty 410 publishes “not published”; LifeMD publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Fifty 410 — unknown; not published. LifeMD — program fee recurs monthly; program fee recurs until cancelled.

Insurance: only LifeMD does coverage work — decisive if there is any chance your plan covers a brand GLP-1, because a covered prescription beats both cash paths on this page.

Evidence: Fifty 410 source-verified (captured 2026-08-05); LifeMD third-party reported (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Fifty 410 and LifeMD

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fifty 410: not published; LifeMD: program fee recurs until cancelled) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings